These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24127478)

  • 21. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
    Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
    Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
    [No Abstract]   [Full Text] [Related]  

  • 22. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
    Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
    Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants.
    Escobar GJ
    J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662
    [No Abstract]   [Full Text] [Related]  

  • 24. Respiratory syncytial virus and recurrent wheeze.
    Blanken MO; Rovers MM; Bont L;
    N Engl J Med; 2013 Aug; 369(8):782-3. PubMed ID: 23964947
    [No Abstract]   [Full Text] [Related]  

  • 25. Respiratory syncytial virus and recurrent wheeze.
    Brand PL
    N Engl J Med; 2013 Aug; 369(8):782. PubMed ID: 23964948
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
    Simões EA; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick L; Groothuis JR;
    J Allergy Clin Immunol; 2010 Aug; 126(2):256-62. PubMed ID: 20624638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term follow-up of Palivizumab administration in children born at 29-32 weeks of gestation.
    Bar-Yoseph R; Haddad J; Hanna M; Kessel I; Kugelman A; Hakim F; Bentur L
    Respir Med; 2019 Apr; 150():149-153. PubMed ID: 30961942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
    Zhu Q; McAuliffe JM; Patel NK; Palmer-Hill FJ; Yang CF; Liang B; Su L; Zhu W; Wachter L; Wilson S; MacGill RS; Krishnan S; McCarthy MP; Losonsky GA; Suzich JA
    J Infect Dis; 2011 Mar; 203(5):674-82. PubMed ID: 21208913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 31. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma.
    Igde M; Kabasakal H; Ozturk O; Karatekin G; Aygun C
    Minerva Pediatr; 2018 Jun; 70(3):252-259. PubMed ID: 29795072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams].
    Korbal P; Mikołajczak A; Szymański W
    Ginekol Pol; 2003 Oct; 74(10):1154-9. PubMed ID: 14669411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
    Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.
    Robbie GJ; Zhao L; Mondick J; Losonsky G; Roskos LK
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4927-36. PubMed ID: 22802243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.